Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Decline in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 59,700 shares, a drop of 35.2% from the February 13th total of 92,200 shares. Based on an average daily volume of 376,300 shares, the short-interest ratio is presently 0.2 days. Currently, 3.4% of the company’s stock are short sold.

Institutional Investors Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Boothbay Fund Management LLC purchased a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned about 2.00% of Avenue Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 17.34% of the company’s stock.

Avenue Therapeutics Trading Up 9.7 %

Avenue Therapeutics stock opened at $0.85 on Monday. The firm has a market cap of $1.74 million, a price-to-earnings ratio of 0.05 and a beta of -0.29. Avenue Therapeutics has a 12 month low of $0.72 and a 12 month high of $12.75. The stock has a fifty day simple moving average of $1.41 and a two-hundred day simple moving average of $1.91.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.